TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07244705: An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instabil

Sponsor: Anbogen Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 66 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,615,610

Rescue Site Savings

+$3,691,380

Unlock Full NCT07244705 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07244705 Rescue Dossier →